ClinicalTrials.gg
TerminatedNCT03552029Updated May 20, 2022Results posted

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

A Phase 1 interventional study of Quizartinib and Milademetan in Acute Myeloid Leukemia, sponsored by Daiichi Sankyo. Terminated at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-20.

Sponsored by Daiichi Sankyo · Phase 1, Interventional, and Treatment

Why this study was terminated
This study was terminated based on a business decision by the Sponsor.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing quizartinib in Leukemia, Myeloid, Acute — 6 open to participants now, 10 under way, 2 of them phase 3. quizartinib · Leukemia, Myeloid, Acute.

Enrollment
24th of 28
10 · median 69
Started
2018
with 3 others
Phase 1
8 of 28
1 open now
Registered
13th of 28
by date
Lead sponsor
10 of 28
Daiichi Sankyo

Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, this one is the 24th largest by enrollment, is one of 4 that started in 2018, is one of 8 in phase 1, and was the 13th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

6 of the 28 studies testing quizartinib in Leukemia, Myeloid, Acute are open now, in 9 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About quizartinib

quizartinib: first FDA approval 2023 (VANFLYTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing quizartinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

Participants with AML that have gone into remission and come back (relapsed) or gone into remission with a number of leukemia cells still in their system (refractory) will be recruited for this study. They will also be positive for FLT3-ITD mutation.

Participants will receive a combined dose of quizartinib and milademetan that have not been approved by the US Food and Drug Administration yet (m).

The combination of these drugs will be provided in different amounts on defined days (dosing schedules).

It is expected that the combination of milademetan and quizartinib will be safe and well tolerated. It is expected that the combination may fight the leukemia better than a single drug.

The study will run for approximately 3 years. There may be up to 156 participants.

The study has 2 parts:

  • Part 1 will test 24-36 participants in approximately 15 study centers globally. Participants will receive two study drugs (milademetan and quizartinib) in different amounts on specific days. Information will be gathered to see what dosing schedule of the drug combination is best (maximum tolerated/recommended dose).
  • Part 2 of the study will confirm the recommended dosing schedule identified in Part 1 is effective. A larger number of participants will receive the recommended dose in approximately 15 additional sites worldwide as necessary, based on the enrollment rate, the population, and the standard of care available to them at the time of enrollment.
03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Relapsed/Refractory
  • Newly Diagnosed
  • Unfit for Chemotherapy
  • Positive for FLT3-ITD Mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has reached ≥18 years old or the age of the age of majority in their country
  • Part 1 (dose escalation): Has FLT3-ITD mutant (≥ 3% FLT3-ITD/total FLT3) AML (primary AML, secondary, or therapy-related AML), and has treatment failure to prior AML therapy or have after prior AML therapy
  • Part 2 (dose expansion): Has FLT3-ITD mutant (≥3% FLT3-ITD/total FLT3) AML (primary, secondary, or therapy-related AML), and has treatment failure to prior AML therapy or have relapsed after prior AML therapy, OR has newly diagnosed AML who are ineligible for intensive induction chemotherapy
  • Has (ECOG) performance status of 0 to 2 (or 3 for patients with newly diagnosed AML between 18 and 74 years old)
  • Has protocol-defined adequate renal, hepatic and cardiac status
  • Is not pregnant, and if not or a surgically sterile male or female, is willing to use a highly effective method upon enrollment, during the course of the study, and for 6 months following the last dose of drug
  • Is able and willing to provide protocol-defined bone marrow /aspirates

Exclusion criteria

Exclusion Criteria:

  • Has central nervous system (CNS) involvement of leukemia - patients with a history of CNS leukemia may be eligible if the CNS leukemia is adequately controlled (defined as no clinical symptoms of CNS disease and at least 2 consecutive lumbar punctures with no evidence of disease prior to study enrollment) after discussion and approval from the Sponsor
  • Has acute promyelocytic leukemia (AML subtype M3)
  • Has uncontrolled or significant cardiovascular disease or >450 ms (average of triplicate determination)
  • Has an uncontrolled infection requiring intravenous antibiotics, antivirals, or antifungals.
  • Has known (HIV) infection, or active or C infection based on positive tests during Screening
  • Has persistent, > Grade 1 non-hematologic toxicity from prior AML therapies
  • Has any history or medical condition, condition, drug/medication use or other condition that might, per protocol or in the opinion of the investigator, compromise:

    1. safety or well-being of the participant or offspring
    2. safety of study staff
    3. analysis of results
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Part 1 - Quizartinib + Milademetan

    Participants with relapsed/refractory FLT3-ITD Mutant AML receive quizartinib + milademetan at increasing and/or decreasing doses and schedules

    Drug: Quizartinib · Drug: Milademetan

  • Experimental
    Part 2 - Cohort 1

    Participants with relapsed/refractory FLT3-ITD Mutant AML receive the recommended dose of quizartinib + milademetan determined by Part 1

    Drug: Quizartinib · Drug: Milademetan

  • Experimental
    Part 2 - Cohort 2

    Participants with newly diagnosed FLT3-ITD Mutant AML unfit for chemotherapy receive the recommended dose of quizartinib + milademetan determined by Part 1

    Drug: Quizartinib · Drug: Milademetan

Interventions

  • 20 or 30 mg tablets for oral administration

    Also known as: AC220, Vanflyta

  • 5, 20, 80 or 200 mg capsules for oral administration

    Also known as: DS-3032b

  • 5, 20, 80 or 200 mg capsules for oral administration; 30, 45, 80, or 100 mg capsules may be utilized

    Also known as: DS-3032b

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLTs) Following Administration of Milademetan in Combination With Quizartinib

    A dose limiting toxicity (DLT) is defined as any non-hematological treatment-emergent adverse event (TEAE) unless incontrovertibly related to disease progression, intercurrent illness, or concomitant medication, that occurs during the DLT evaluation period (28 days) in each dose level cohort, and is Grade 3 or higher according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, with exceptions specified: Grade 3 or higher aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels, OR elevation in total bilirubin ≥3.0 × upper limit of normal (ULN) that does not return to ≤Grade 2 elevation within 7 days. Absolute neutrophil count (ANC) \<0.5 × 10\^9/L, platelets \<20 × 10\^9/L, and marrow cellularity \<5% at 6 weeks or later from start of therapy without any evidence of leukemia.

    Time frame: Baseline up to 28 days (Cycle 1) from the start of study drug administration

  2. Number of Participants With Any Treatment-emergent Adverse Events by System Organ Class Following Administration of Milademetan in Combination With Quizartinib

    A treatment-emergent adverse event (TEAE) is defined as an adverse event (AE) that emerges during the treatment period (from date of first dose up to 35 days after the last dose of the study treatment), having been absent at pretreatment; or reemerges during treatment, having been present at baseline but stopped prior to treatment; or worsens in severity after starting treatment related to the pretreatment state, when the AE is continuous. AEs collected after 35 days after the last dose of study drug were not considered TEAEs unless they were treatment-related.

    Time frame: Baseline up to 35 days after last dose of study drug, up to approximately 2 years 3 months

Secondary outcomes

  1. Number of Participants With Best Overall Response Following Administration of Milademetan in Combination With Quizartinib

    Based on European LeukemiaNet criteria, complete remission (CR) was bone marrow (BM) blasts \<5%, absence of circulating blasts/blasts with Auer rods, absence of extramedullary disease (EMD), absolute neutrophil count (ANC) ≥1.0×10\^9/L, and platelet count ≥100×10\^9/L; CR with Incomplete Blood Count Recovery (CRi): all CR criteria except for residual neutropenia or thrombocytopenia; Morphologic Leukemia Free State (MLFS): BM blasts \<5%, absence of blasts with Auer rods, absence of EMD, and no hematologic recovery required; Partial Remission (PR): decrease of BM blast percentage by at least 50% (to 5% to 25%) and all criteria of CR; Stable disease: absence of CR, CRi, MLFS, or PR, and criteria for progressive disease (PD) not met; Relapse (after CR/CRi): BM blasts ≥5%, or reappearance of leukemic blasts, or EMD development; and PD: increase in BM blast % and/or increase of absolute blast counts: \>50% increase in marrow blasts over baseline, \>50% increase in peripheral blasts, or new EMD.

    Time frame: Baseline up to first documented response, disease progression, withdrawal, or death (whichever occurs first), up to approximately 2 years 3 months

  2. Overall Response Rate Following Administration of Milademetan in Combination With Quizartinib

    Overall response rate was defined as the number of participants with composite Complete Remission (CRc)+Morphological Leukemia Free State (MLFS)+Partial Remission (PR) based on the European LeukemiaNet criteria. Based on the European LeukemiaNet criteria, CRc was defined as complete remission (CR) as bone marrow (BM) blasts \<5%, absence of circulating blasts/blasts with Auer rods, absence of extramedullary disease (EMD), absolute neutrophil count (ANC) ≥1.0×10\^9/L, and platelet count ≥100×10\^9/L; CR with Incomplete Blood Count Recovery (CRi): all CR criteria except for residual neutropenia or thrombocytopenia; Morphologic Leukemia Free State (MLFS): BM blasts \<5%, absence of blasts with Auer rods, absence of EMD, and no hematologic recovery required; Partial Remission (PR): decrease of BM blast percentage by at least 50% (to 5% to 25%) and all criteria of CR.

    Time frame: Baseline up to first documented response, disease progression, withdrawal, or death (whichever occurs first), up to approximately 2 years 3 months

07

Results

Posted May 20, 2022
Limitations and caveats
This study was terminated based on a business decision by the Sponsor and was not due to a safety concern.

Participant flow

A total of 10 out of the 22 screened participants who met all inclusion criteria and no exclusion criteria were enrolled in the study at 8 clinic sites in the United States. Only Part 1 is reported since the study terminated prior to Part 2.

Participant flow — Overall Study
MilestonePart 1, Cohort 1: Quizartinib + MilademetanPart 1, Cohort 1A: Quizartinib + Milademetan
Started46
Completed00
Not completed46
Withdrew: Death30
Withdrew: Adverse event10
Withdrew: Lack of efficacy02
Withdrew: Physician decision01
Withdrew: Study terminated by sponsor01
Withdrew: Other02

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities (DLTs) Following Administration of Milademetan in Combination With Quizartinib

A dose limiting toxicity (DLT) is defined as any non-hematological treatment-emergent adverse event (TEAE) unless incontrovertibly related to disease progression, intercurrent illness, or concomitant medication, that occurs during the DLT evaluation period (28 days) in each dose level cohort, and is Grade 3 or higher according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, with exceptions specified: Grade 3 or higher aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels, OR elevation in total bilirubin ≥3.0 × upper limit of normal (ULN) that does not return to ≤Grade 2 elevation within 7 days. Absolute neutrophil count (ANC) \<0.5 × 10\^9/L, platelets \<20 × 10\^9/L, and marrow cellularity \<5% at 6 weeks or later from start of therapy without any evidence of leukemia.

Time frame:
Baseline up to 28 days (Cycle 1) from the start of study drug administration
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLTs) Following Administration of Milademetan in Combination With Quizartinib
ParticipantsPart 1, Cohort 1: Quizartinib + MilademetanPart 1, Cohort 1A: Quizartinib + Milademetan
Number of Participants With Dose Limiting Toxicities (DLTs) Following Administration of Milademetan in Combination With Quizartinib10
PrimaryNumber of Participants With Any Treatment-emergent Adverse Events by System Organ Class Following Administration of Milademetan in Combination With Quizartinib

A treatment-emergent adverse event (TEAE) is defined as an adverse event (AE) that emerges during the treatment period (from date of first dose up to 35 days after the last dose of the study treatment), having been absent at pretreatment; or reemerges during treatment, having been present at baseline but stopped prior to treatment; or worsens in severity after starting treatment related to the pretreatment state, when the AE is continuous. AEs collected after 35 days after the last dose of study drug were not considered TEAEs unless they were treatment-related.

Time frame:
Baseline up to 35 days after last dose of study drug, up to approximately 2 years 3 months
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Events by System Organ Class Following Administration of Milademetan in Combination With Quizartinib
ParticipantsPart 1, Cohort 1: Quizartinib + MilademetanPart 1, Cohort 1A: Quizartinib + Milademetan
Any TEAEs46
Any Blood and Lymphatic System Disorders25
Any Cardiac Disorders12
Any Ear and Labyrinth Disorders11
Any Eye Disorders20
Any Gastrointestinal Disorders46
Any General Disorders and Administration Site Conditions35
Any Immune System Disorders10
Any Infections and Infestations41
Any Injury, Poisoning and Procedural Complications03
Any Investigations35
Any Metabolism and Nutrition Disorders45
Any Musculoskeletal and Connective Tissue Disorders24
Any Nervous System Disorders43
Any Psychiatric Disorders22
Any Renal and Urinary Disorders12
Any Respiratory, Thoracic, and Mediastinal Disorders44
Any Skin and Subcutaneous Tissue Disorders35
Any Vascular Disorders31
SecondaryNumber of Participants With Best Overall Response Following Administration of Milademetan in Combination With Quizartinib

Based on European LeukemiaNet criteria, complete remission (CR) was bone marrow (BM) blasts \<5%, absence of circulating blasts/blasts with Auer rods, absence of extramedullary disease (EMD), absolute neutrophil count (ANC) ≥1.0×10\^9/L, and platelet count ≥100×10\^9/L; CR with Incomplete Blood Count Recovery (CRi): all CR criteria except for residual neutropenia or thrombocytopenia; Morphologic Leukemia Free State (MLFS): BM blasts \<5%, absence of blasts with Auer rods, absence of EMD, and no hematologic recovery required; Partial Remission (PR): decrease of BM blast percentage by at least 50% (to 5% to 25%) and all criteria of CR; Stable disease: absence of CR, CRi, MLFS, or PR, and criteria for progressive disease (PD) not met; Relapse (after CR/CRi): BM blasts ≥5%, or reappearance of leukemic blasts, or EMD development; and PD: increase in BM blast % and/or increase of absolute blast counts: \>50% increase in marrow blasts over baseline, \>50% increase in peripheral blasts, or new EMD.

Time frame:
Baseline up to first documented response, disease progression, withdrawal, or death (whichever occurs first), up to approximately 2 years 3 months
Reported as:
Count of participants · Participants
Number of Participants With Best Overall Response Following Administration of Milademetan in Combination With Quizartinib
ParticipantsPart 1, Cohort 1: Quizartinib + MilademetanPart 1, Cohort 1A: Quizartinib + Milademetan
Complete remission (CR)00
Complete Remission with Partial Hematological Recovery (CRh)00
Complete Remission with Incomplete Blood Count Recovery (CRi)13
Morphologic Leukemia Free State (MLFS)00
Partial Remission (PR)00
Stable Disease (SD)12
Relapse00
Missing21
SecondaryOverall Response Rate Following Administration of Milademetan in Combination With Quizartinib

Overall response rate was defined as the number of participants with composite Complete Remission (CRc)+Morphological Leukemia Free State (MLFS)+Partial Remission (PR) based on the European LeukemiaNet criteria. Based on the European LeukemiaNet criteria, CRc was defined as complete remission (CR) as bone marrow (BM) blasts \<5%, absence of circulating blasts/blasts with Auer rods, absence of extramedullary disease (EMD), absolute neutrophil count (ANC) ≥1.0×10\^9/L, and platelet count ≥100×10\^9/L; CR with Incomplete Blood Count Recovery (CRi): all CR criteria except for residual neutropenia or thrombocytopenia; Morphologic Leukemia Free State (MLFS): BM blasts \<5%, absence of blasts with Auer rods, absence of EMD, and no hematologic recovery required; Partial Remission (PR): decrease of BM blast percentage by at least 50% (to 5% to 25%) and all criteria of CR.

Time frame:
Baseline up to first documented response, disease progression, withdrawal, or death (whichever occurs first), up to approximately 2 years 3 months
Reported as:
Count of participants · Participants
Overall Response Rate Following Administration of Milademetan in Combination With Quizartinib
ParticipantsPart 1, Cohort 1: Quizartinib + MilademetanPart 1, Cohort 1A: Quizartinib + Milademetan
Overall Response Rate Following Administration of Milademetan in Combination With Quizartinib13

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) were collected from date of first dose up to 35 days after last dose of study drug, up to approximately 2 years 3 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1, Cohort 1: Quizartinib + Milademetan3/4 (75%)4/4 (100%)4/4 (100%)
Part 1, Cohort 1A: Quizartinib + Milademetan1/6 (16.7%)3/6 (50%)6/6 (100%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPart 1, Cohort 1: Quizartinib + MilademetanPart 1, Cohort 1A: Quizartinib + Milademetan
AnaemiaBlood and lymphatic system disorders1/40/6
Febrile neutropeniaBlood and lymphatic system disorders1/40/6
ThrombocytopeniaBlood and lymphatic system disorders1/40/6
BradycardiaCardiac disorders1/40/6
Arthritis infectiveInfections and infestations1/40/6
SepsisInfections and infestations1/40/6
Septic shockInfections and infestations1/40/6
Sinusitis fungalInfections and infestations1/40/6
HypoxiaRespiratory, thoracic and mediastinal disorders1/41/6
HaematomaVascular disorders1/40/6
Most frequent other events
Showing 10 of 138
Most frequent other events
EventPart 1, Cohort 1: Quizartinib + MilademetanPart 1, Cohort 1A: Quizartinib + Milademetan
HypomagnesaemiaMetabolism and nutrition disorders3/42/6
CoughRespiratory, thoracic and mediastinal disorders3/42/6
DiarrhoeaGastrointestinal disorders2/44/6
NauseaGastrointestinal disorders2/44/6
FatigueGeneral disorders1/44/6
Decreased appetiteMetabolism and nutrition disorders2/44/6
HypokalaemiaMetabolism and nutrition disorders2/44/6
AnaemiaBlood and lymphatic system disorders1/43/6
Febrile neutropeniaBlood and lymphatic system disorders2/41/6
VomitingGastrointestinal disorders2/43/6

Baseline characteristics

Demographics and baseline characteristics were assessed in the Enrolled Analysis Set.

Age, Continuous
Age, Continuous(years)Part 1, Cohort 1: Quizartinib + MilademetanPart 1, Cohort 1A: Quizartinib + MilademetanTotal
Median64 (51 to 72)65 (51 to 81)64 (51 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Part 1, Cohort 1: Quizartinib + MilademetanPart 1, Cohort 1A: Quizartinib + MilademetanTotal
Female022
Male448
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1, Cohort 1: Quizartinib + MilademetanPart 1, Cohort 1A: Quizartinib + MilademetanTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White459
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(participants)Part 1, Cohort 1: Quizartinib + MilademetanPart 1, Cohort 1A: Quizartinib + MilademetanTotal
United States4610
08

Study locations

8 sites
  • Ronald Reagan Medical Center, UCLA
    Los Angeles, California 90095, United States
  • Yale Cancer Center
    New Haven, Connecticut 06510, United States
  • University of Kansas Cancer Center
    Fairway, Kansas 66205, United States
  • Rogel Cancer Center, University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Roswell Park Comprehensive Cancer Center
    Buffalo, New York 14263, United States
  • Duke University Cancer Center
    Durham, North Carolina 27710, United States
  • Sidney Kimmel Cancer Center, Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Apr 2021, 27 months.

Results were first posted in May 2022, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2018
First posted
Jun 11, 2018
StartActual
Dec 12, 2018
Primary completionActual
Apr 1, 2021
CompletionActual
Apr 1, 2021
Results first posted
May 20, 2022
Last update
May 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03552029
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Jun 11, 2018
Start date
Dec 12, 2018
Primary completion
Apr 1, 2021
Completion
Apr 1, 2021
Results posted
May 20, 2022
Last update
May 20, 2022

Study contacts

Clinical Team Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Quizartinib · Milademetan

Start the discussion